FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2174752775> ?p ?o ?g. }

• W2174752775 endingPage "e32" @default.
• W2174752775 startingPage "e23" @default.
• W2174752775 abstract "Background Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR). Methods In this prospective international cohort study, HIV-positive adult participants (aged ≥16 years) from the D:A:D study (based in Europe, the USA, and Australia) with first eGFR greater than 90 mL/min per 1·73 m2 were followed from baseline (first eGFR measurement after Jan 1, 2004) until the occurrence of one of the following: chronic kidney disease; last eGFR measurement; Feb 1, 2014; or final visit plus 6 months (whichever occurred first). Chronic kidney disease was defined as confirmed (>3 months apart) eGFR lower than 60 mL/min per 1·73 m2. The primary outcome was the occurrence of chronic kidney disease. Poisson regression was used to estimate the incidence rate of chronic kidney disease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir-boosted protease inhibitors, or abacavir. Findings Between Jan 1, 2004, and July 26, 2013, 23 905 eligible individuals from the D:A:D study were included. Participants had a median baseline eGFR of 110 mL/min per 1·73 m2 (IQR 100–125), a median age of 39 years (33–45), and median CD4 cell count of 441 cells per mm3 (294–628). During a median follow-up of 7·2 years (IQR 5·1–8·9), 285 (1%) of 23 905 people developed chronic kidney disease (incidence 1·76 per 1000 person-years of follow-up [95% CI 1·56–1·97]). After adjustment, we recorded a significant increase in chronic kidney disease associated with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1·14 [95% CI 1·10–1·19], p<0·0001), ritonavir-boosted atazanavir (1·20 [1·13–1·26], p<0·0001), and ritonavir-boosted lopinavir (1·11 [1·06–1·16], p<0·0001), but not other ritonavir-boosted protease inhibitors or abacavir. Interpretation In people with normal renal function, the annual incidence of chronic kidney disease increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy. Although the absolute number of new cases of chronic kidney disease was modest, treatment with these antiretrovirals might result in an increasing and cumulative risk of chronic kidney disease. Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney disease should be closely monitored. Funding The Highly Active Antiretroviral Therapy Oversight Committee. Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR). In this prospective international cohort study, HIV-positive adult participants (aged ≥16 years) from the D:A:D study (based in Europe, the USA, and Australia) with first eGFR greater than 90 mL/min per 1·73 m2 were followed from baseline (first eGFR measurement after Jan 1, 2004) until the occurrence of one of the following: chronic kidney disease; last eGFR measurement; Feb 1, 2014; or final visit plus 6 months (whichever occurred first). Chronic kidney disease was defined as confirmed (>3 months apart) eGFR lower than 60 mL/min per 1·73 m2. The primary outcome was the occurrence of chronic kidney disease. Poisson regression was used to estimate the incidence rate of chronic kidney disease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir-boosted protease inhibitors, or abacavir. Between Jan 1, 2004, and July 26, 2013, 23 905 eligible individuals from the D:A:D study were included. Participants had a median baseline eGFR of 110 mL/min per 1·73 m2 (IQR 100–125), a median age of 39 years (33–45), and median CD4 cell count of 441 cells per mm3 (294–628). During a median follow-up of 7·2 years (IQR 5·1–8·9), 285 (1%) of 23 905 people developed chronic kidney disease (incidence 1·76 per 1000 person-years of follow-up [95% CI 1·56–1·97]). After adjustment, we recorded a significant increase in chronic kidney disease associated with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1·14 [95% CI 1·10–1·19], p<0·0001), ritonavir-boosted atazanavir (1·20 [1·13–1·26], p<0·0001), and ritonavir-boosted lopinavir (1·11 [1·06–1·16], p<0·0001), but not other ritonavir-boosted protease inhibitors or abacavir. In people with normal renal function, the annual incidence of chronic kidney disease increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy. Although the absolute number of new cases of chronic kidney disease was modest, treatment with these antiretrovirals might result in an increasing and cumulative risk of chronic kidney disease. Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney disease should be closely monitored." @default.
• W2174752775 created "2016-06-24" @default.
• W2174752775 creator A5001375239 @default.
• W2174752775 creator A5001968229 @default.
• W2174752775 creator A5027160828 @default.
• W2174752775 creator A5071369844 @default.
• W2174752775 creator A5072537371 @default.
• W2174752775 creator A5074980560 @default.
• W2174752775 creator A5078701955 @default.
• W2174752775 creator A5086527016 @default.
• W2174752775 creator A5087896662 @default.
• W2174752775 creator A5088502098 @default.
• W2174752775 date "2016-01-01" @default.
• W2174752775 modified "2023-10-06" @default.
• W2174752775 title "Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study" @default.
• W2174752775 cites W1851489612 @default.
• W2174752775 cites W1967879506 @default.
• W2174752775 cites W1970735835 @default.
• W2174752775 cites W1986694485 @default.
• W2174752775 cites W2004567313 @default.
• W2174752775 cites W2008050189 @default.
• W2174752775 cites W2018761667 @default.
• W2174752775 cites W2029335853 @default.
• W2174752775 cites W2034122697 @default.
• W2174752775 cites W2055922999 @default.
• W2174752775 cites W2056779298 @default.
• W2174752775 cites W2058256907 @default.
• W2174752775 cites W2061817517 @default.
• W2174752775 cites W2066473256 @default.
• W2174752775 cites W2070237659 @default.
• W2174752775 cites W2080152031 @default.
• W2174752775 cites W2083692806 @default.
• W2174752775 cites W2088915106 @default.
• W2174752775 cites W2091295275 @default.
• W2174752775 cites W2099509337 @default.
• W2174752775 cites W2107027814 @default.
• W2174752775 cites W2110559078 @default.
• W2174752775 cites W2118020641 @default.
• W2174752775 cites W2147020182 @default.
• W2174752775 cites W2149717057 @default.
• W2174752775 cites W4211025575 @default.
• W2174752775 cites W4237481231 @default.
• W2174752775 cites W4296391115 @default.
• W2174752775 doi "https://doi.org/10.1016/s2352-3018(15)00211-8" @default.
• W2174752775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26762990" @default.
• W2174752775 hasPublicationYear "2016" @default.
• W2174752775 type Work @default.
• W2174752775 sameAs 2174752775 @default.
• W2174752775 citedByCount "149" @default.
• W2174752775 countsByYear W21747527752015 @default.
• W2174752775 countsByYear W21747527752016 @default.
• W2174752775 countsByYear W21747527752017 @default.
• W2174752775 countsByYear W21747527752018 @default.
• W2174752775 countsByYear W21747527752019 @default.
• W2174752775 countsByYear W21747527752020 @default.
• W2174752775 countsByYear W21747527752021 @default.
• W2174752775 countsByYear W21747527752022 @default.
• W2174752775 countsByYear W21747527752023 @default.
• W2174752775 crossrefType "journal-article" @default.
• W2174752775 hasAuthorship W2174752775A5001375239 @default.
• W2174752775 hasAuthorship W2174752775A5001968229 @default.
• W2174752775 hasAuthorship W2174752775A5027160828 @default.
• W2174752775 hasAuthorship W2174752775A5071369844 @default.
• W2174752775 hasAuthorship W2174752775A5072537371 @default.
• W2174752775 hasAuthorship W2174752775A5074980560 @default.
• W2174752775 hasAuthorship W2174752775A5078701955 @default.
• W2174752775 hasAuthorship W2174752775A5086527016 @default.
• W2174752775 hasAuthorship W2174752775A5087896662 @default.
• W2174752775 hasAuthorship W2174752775A5088502098 @default.
• W2174752775 hasBestOaLocation W21747527754 @default.
• W2174752775 hasConcept C119060515 @default.
• W2174752775 hasConcept C126189478 @default.
• W2174752775 hasConcept C126322002 @default.
• W2174752775 hasConcept C142462285 @default.
• W2174752775 hasConcept C159641895 @default.
• W2174752775 hasConcept C167704817 @default.
• W2174752775 hasConcept C188816634 @default.
• W2174752775 hasConcept C201903717 @default.
• W2174752775 hasConcept C203014093 @default.
• W2174752775 hasConcept C2777182164 @default.
• W2174752775 hasConcept C2778414717 @default.
• W2174752775 hasConcept C2778653478 @default.
• W2174752775 hasConcept C2779134260 @default.
• W2174752775 hasConcept C2779298103 @default.
• W2174752775 hasConcept C2780091579 @default.
• W2174752775 hasConcept C2993143319 @default.
• W2174752775 hasConcept C3008058167 @default.
• W2174752775 hasConcept C3013748606 @default.
• W2174752775 hasConcept C44249647 @default.
• W2174752775 hasConcept C524204448 @default.
• W2174752775 hasConcept C71924100 @default.
• W2174752775 hasConcept C72563966 @default.
• W2174752775 hasConcept C88879693 @default.
• W2174752775 hasConceptScore W2174752775C119060515 @default.
• W2174752775 hasConceptScore W2174752775C126189478 @default.
• W2174752775 hasConceptScore W2174752775C126322002 @default.
• W2174752775 hasConceptScore W2174752775C142462285 @default.
• W2174752775 hasConceptScore W2174752775C159641895 @default.

• next